ClinicalTrials.gg
RecruitingNCT07048002INSPIREUpdated Nov 24, 2025

Interventions for Silent Brain Infarction and Perioperative Neurocognitive Disorders in Cardiovascular Surgery

An interventional study of Managements for NeuroFirst target bundle and Managements for institutional routine in Silent Brain Infarction, Neurocognitive Disorders and Cardiac Surgery, sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital. Recruiting at 5 sites in China. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2025-11-24.

Sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
912
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Neurocognitive Disorders with a site in China — 13 open to participants now, 14 under way, 1 of them phase 3. Neurocognitive Disorders · China.

Planned enrollment
4th of 15
912 · median 264
Started
2025
with 1 other
No phase
9 of 22
6 open now
Primary completion
2027-10
later than 7 of 13 live
Registered
16th of 22
by date
Lead sponsor
3 of 22
Chinese Academy of Medical Sciences, Fuwai Hospital

Among the 22 studies in Neurocognitive Disorders with a site in China, this one is the 4th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2025, is one of 9 with no phase, reaches primary completion later than 7 of the 13 other live ones, and was the 16th registered.

Neurocognitive Disorders

275 studies on the registry are indexed under Neurocognitive Disorders; 91 are open to participants now.

Browse Neurocognitive Disorders studies →

Open to participants now

13 of the 22 studies in Neurocognitive Disorders with a site in China are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 61 Neurocognitive Disorders studies recruiting now, 38 (62%) set no upper age limit and 2 (3%) stop at 75 or younger; 4 take children under 18; 17 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Neurocognitive Disorders with a site in China, or all of them as a file.
02

Study summary

the purpose of the study is to investigate whether a combined anesthetic targets bundle, known as the NeuroFirst strategy, focused on neurological protection, can reduce the incidence of silent brain infarction (SBI) and perioperative neurocognitive disorders (PND) in patients undergoing cardiac surgery. Additionally, the trial will assess the safety of this strategy.

The NeuroFirst target bundle incorporates multiple parameters, including mean arterial pressure (MAP), bispectral index (BIS), regional cerebral oxygen saturation (rSO2), and arterial inflow temperature during cardiopulmonary bypass.

The primary question this study seeks to answer is: Does the NeuroFirst strategy reduce the incidence of SBI and PND in cardiac surgery?

To address this, researchers will compare the NeuroFirst strategy with routine institutional practices based on published guidelines. Participants will be randomly assigned to either the NeuroFirst group or the routine care group. All participants will undergo magnetic resonance imaging (MRI), be assessed using the Confusion Assessment Method (CAM) and the Montreal Cognitive Assessment (MoCA), and be followed for up to one year postoperatively.

03

Conditions studied

  • Silent Brain Infarction
  • Neurocognitive Disorders
  • Cardiac Surgery
  • Neuroprotective
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female adult patients aged 60 years or older
  • Receiving elective cardiovascular surgery with cardiopulmonary bypass
  • Written provided

Exclusion criteria

Exclusion criteria:

  • to MRI scanning
  • Not suitable for receiving interventions to achieve NeuroFirst target bundle
  • Unable to receive neuro-cognitive evaluation due to language, vision, or hearing impairments
  • Breastfeeding or pregnancy
  • Terminal illness with a of less than 3 months
  • Mental or legal disability
  • current enrollment in other interventional study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
912 participants (estimated)

Study arms

  • Experimental
    NeuroFirst target bundle

    Management for NeuroFirst target bundle

    Other: Managements for NeuroFirst target bundle

  • Active comparator
    Routine Management

    Management for institutional routine in accordance with published guidelines

    Other: Managements for institutional routine

Interventions

  • OtherManagements for NeuroFirst target bundle

    In the intervention group, patient management aims to achieve the NeuroFirst target bundle, including 1) mean arterial pressure (MAP) 65-90 mmHg, 2) bispectral index (BIS) 40-60, 3) regional cerebral oxygen saturation (rSO2)≥ 60% , and 4) arterial inflow temperature \<37 ℃ and rewarming rate \< 0.5 ℃/min after exceeding 30℃ during CPB. To achieve this target bundle, pharmacologic agents, fluid resuscitation, blood transfusion, and other therapeutic modalities will be utilized. These interventions are guided by comprehensive intraoperative monitoring, including conventional hemodynamic monitoring, invasive or non-invasive cardiac output and vascular resistance assessments.

  • OtherManagements for institutional routine

    MAP, BIS, cerebral rSO2 and arterial inflow temperature during CPB rewarming, will be managed according to institutional routine in accordance with published guidelines.

06

What researchers measure

Primary outcomes

  1. the 7-day incidence of new-onset silent brain infarction (SBI)

    New-onset silent brain infarction refers to newly developed cerebral infarctions detected on MRI, compared with the preoperative MRI, in the absence of any corresponding clinical symptoms of cerebral infarction.

    Time frame: within 7 days postoperatively

Secondary outcomes

  1. Key Secondary Outcome: the 30-day incidence of perioperative neurocognitive disorders (PND)

    The incidence of 30-day PND includes the incidence of postoperative delirium in hospital and perioperative neurocognitive disorders within 30 days after surgery

    Time frame: within 30 days postoperatively

  2. the 5-day incidence of postoperative delirium

    the incedence of delirium evaluated by CAM/CAM-ICU

    Time frame: within five days postoperatively

  3. the 30-day incidence of new-onset overt stroke

    Postoperative new-onset overt stroke was defined as any new ischemic or hemorrhagic cerebrovascular event after surgery with focal or global neurological (motor, sensory or cognitive) dysfunction lasting at least 24 h. And a broadened stroke definition also including neurological dysfunction of \<24 h duration with corresponding evidence of central nervous system hemorrhage or infarction (including pathological, imaging, or other objective evidence of cerebral, spinal cord or retinal focal ischemic injury in a defined vascular distribution).

    Time frame: within 30 days postoperatively

  4. the 1-year incidence of new-onset overt stroke

    Postoperative new-onset overt stroke was defined as any new ischemic or hemorrhagic cerebrovascular event after surgery with focal or global neurological (motor, sensory or cognitive) dysfunction lasting at least 24 h. And a broadened stroke definition also including neurological dysfunction of \<24 h duration with corresponding evidence of central nervous system hemorrhage or infarction (including pathological, imaging, or other objective evidence of cerebral, spinal cord or retinal focal ischemic injury in a defined vascular distribution).

    Time frame: within 1 year postoperatively

  5. the 1-year incidence of perioperative neurocognitive disorders (PND)

    the incidence of perioperative neurocognitive disorders (PND)

    Time frame: within 1 year postoperatively

  6. the 30-day composite incidence of major adverse events

    Major adverse events refer to renal insufficiency, myocardial infarction, pulmonary embolism, seizure and all-cause mortality.

    Time frame: within 30 days postoperatively

  7. the 1-year composite incidence of major adverse events

    Major adverse events refer to renal insufficiency, myocardial infarction, pulmonary embolism, seizure and all-cause mortality.

    Time frame: within 1 year postoperatively

  8. the 30-day incidence of transient ischemic attack (TIA)

    TIA is defined as focal arterial ischemia with transient symptoms (lasting \<24 hours) and without evidence of infarction by pathology or imaging.

    Time frame: within 30 days postoperatively

  9. the 1-year incidence of transient ischemic attack (TIA)

    TIA is defined as focal arterial ischemia with transient symptoms (lasting \<24 hours) and without evidence of infarction by pathology or imaging.

    Time frame: within 1 year postoperatively

Other outcomes

  1. Length of stay (LOS) in intensive care unit (ICU)

    Length of stay (LOS) in intensive care unit (ICU) postoperatively

    Time frame: Perioperative

  2. Length of stay (LOS) in hospital

    Length of stay (LOS) in hospital postoperatively

    Time frame: Perioperative

  3. Hospitalization cost

    Operative and postoperative hospitalization cost

    Time frame: Perioperative

07

Study locations

5 of 5 sites recruiting
  • Beijing Chaoyang Hospital,Capital Medical University
    Beijing, Beijing Municipality 100020, China
    Recruiting
    • Changwei Wei, M.D. · Contactwcw0025@sina.com · 8610 85231330
    • Changwei Wei, M.D. · Principal investigator
  • State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College
    Beijing, Beijing Municipality 100037, China
    Recruiting
    • Jia Shi, M.D. · Contactshijia@fuwai.com · 86 10 88322467
    • Jia Shi, M.D. · Principal investigator
  • Xuanwu Hospital,Capital Medical University
    Beijing, Beijing Municipality 100053, China
    Recruiting
    • Lei Zhao, M.D. · Contactzhaoalei@sina.com · 86 10 83199352
    • Lei Zhao, M.D. · Principal investigator
  • Beijing Tiantan Hospital, Capital Medical University
    Beijing, Beijing Municipality 100160, China
    Recruiting
    • Shu Li, M.D. · Contactlishu@bjtth.org · 86 10 59976658
    • Shu Li, M.D. · Principal investigator
  • The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430014, China
    Recruiting
    • Jingli Chen, M.D. · Contactchenjinli2001@sina.com · 8610 82811446
    • Jingli Chen, M.D. · Principal investigator
08

References and documents

Publications

  • Uysal S, Lin HM, Trinh M, Park CH, Reich DL. Optimizing cerebral oxygenation in cardiac surgery: A randomized controlled trial examining neurocognitive and perioperative outcomes. J Thorac Cardiovasc Surg. 2020 Mar;159(3):943-953.e3. doi: 10.1016/j.jtcvs.2019.03.036. Epub 2019 Mar 29. PubMed 31056357 ↗
  • Maheshwari A, McCormick PJ, Sessler DI, Reich DL, You J, Mascha EJ, Castillo JG, Levin MA, Duncan AE. Prolonged concurrent hypotension and low bispectral index ('double low') are associated with mortality, serious complications, and prolonged hospitalization after cardiac surgery. Br J Anaesth. 2017 Jul 1;119(1):40-49. doi: 10.1093/bja/aex095. PubMed 28974062 ↗
  • Descamps R, Amour J, Besnier E, Bougle A, Charbonneau H, Charvin M, Cholley B, Desebbe O, Fellahi JL, Frasca D, Labaste F, Lena D, Mahjoub Y, Mertes PM, Molliex S, Moury PH, Moussa MD, Oilleau JF, Ouattara A, Provenchere S, Rozec B, Parienti JJ, Fischer MO; OPTIPAM investigators. Perioperative individualized hemodynamic optimization according to baseline mean arterial pressure in cardiac surgery patients: Rationale and design of the OPTIPAM randomized trial. Am Heart J. 2023 Jul;261:10-20. doi: 10.1016/j.ahj.2023.03.005. Epub 2023 Mar 18. PubMed 36934980 ↗
  • Gerstenecker A, Norling AM, Jacob A, Lazar RM. Silent Brain Infarction, Delirium, and Cognition in Three Invasive Cardiovascular Procedures: a Systematic Review. Neuropsychol Rev. 2023 Jun;33(2):474-491. doi: 10.1007/s11065-022-09548-1. Epub 2022 Jul 8. PubMed 35804216 ↗
  • Newman MF, Kirchner JL, Phillips-Bute B, Gaver V, Grocott H, Jones RH, Mark DB, Reves JG, Blumenthal JA; Neurological Outcome Research Group and the Cardiothoracic Anesthesiology Research Endeavors Investigators. Longitudinal assessment of neurocognitive function after coronary-artery bypass surgery. N Engl J Med. 2001 Feb 8;344(6):395-402. doi: 10.1056/NEJM200102083440601. PubMed 11172175 ↗
  • Brown CH 4th, Probert J, Healy R, Parish M, Nomura Y, Yamaguchi A, Tian J, Zehr K, Mandal K, Kamath V, Neufeld KJ, Hogue CW. Cognitive Decline after Delirium in Patients Undergoing Cardiac Surgery. Anesthesiology. 2018 Sep;129(3):406-416. doi: 10.1097/ALN.0000000000002253. PubMed 29771710 ↗
  • Cheng C, Wan H, Cong P, Huang X, Wu T, He M, Zhang Q, Xiong L, Tian L. Targeting neuroinflammation as a preventive and therapeutic approach for perioperative neurocognitive disorders. J Neuroinflammation. 2022 Dec 12;19(1):297. doi: 10.1186/s12974-022-02656-y. PubMed 36503642 ↗
  • Indja B, Woldendorp K, Vallely MP, Grieve SM. Silent Brain Infarcts Following Cardiac Procedures: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2019 May 7;8(9):e010920. doi: 10.1161/JAHA.118.010920. PubMed 31017035 ↗
  • Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003 Mar 27;348(13):1215-22. doi: 10.1056/NEJMoa022066. PubMed 12660385 ↗
  • Fanning JP, Wong AA, Fraser JF. The epidemiology of silent brain infarction: a systematic review of population-based cohorts. BMC Med. 2014 Jul 9;12:119. doi: 10.1186/s12916-014-0119-0. PubMed 25012298 ↗
  • Sultan I, Bianco V, Kilic A, Jovin T, Jadhav A, Jankowitz B, Aranda-Michel E, D'angelo MP, Navid F, Wang Y, Thoma F, Gleason TG. Predictors and Outcomes of Ischemic Stroke After Cardiac Surgery. Ann Thorac Surg. 2020 Aug;110(2):448-456. doi: 10.1016/j.athoracsur.2020.02.025. Epub 2020 Mar 19. PubMed 32199830 ↗
  • Wang L, Li S, Devereaux PJ, Lv H, Li T, Zhang L, An Y, Chen J, Wei C, Zhao L, Peng Y, Shi J. Interventions for Silent Brain Infarction and Perioperative Neurocognitive Disorders in Cardiovascular Surgery (INSPIRE): study protocol for a multicentre randomised controlled trial. BMJ Open. 2026 Jun 19;16(6):e116246. doi: 10.1136/bmjopen-2026-116246. PubMed 42320960 ↗

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared in order to protect participant privacy and confidentiality. Additionally, the consent obtained from participants does not include provisions for data sharing, in accordance with ethical guidelines and institutional policies.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Oct 2027, 27 months after the start.

Of 80 non-industry interventional studies with no phase under Neurocognitive Disorders, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 46. This study's planned 27 months is close to that.

Counting every sponsor, half of 83 studies reached it within 27 months; a quarter within 15 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2025
First posted
Jul 2, 2025
StartActual
Jul 6, 2025
Primary completionEst.
Oct 31, 2027
CompletionEst.
Oct 31, 2028
Last update
Nov 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07048002
Responsible party
SHI Jia (Vice Chair, Department of Anesthesiology, Chinese Academy of Medical Sciences, Fuwai Hospital) — Principal investigator
First posted
Jul 2, 2025
Start date
Jul 6, 2025
Primary completion
Oct 31, 2027 (estimated)
Completion
Oct 31, 2028 (estimated)
Last update
Nov 24, 2025

Study contacts

Jia Shi, M.D.
Contact
shijia@fuwai.com
+86 10 88322467

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion